Zacks Research Forecasts Reduced Earnings for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Equities research analysts at Zacks Research lowered their Q2 2025 earnings per share estimates for AngioDynamics in a research note issued to investors on Wednesday, October 23rd. Zacks Research analyst D. Dey now anticipates that the medical instruments supplier will earn ($0.12) per share for the quarter, down from their prior forecast of ($0.10). The consensus estimate for AngioDynamics' current full-year earnings is ($0.41) per share. Zacks Research also issued estimates for AngioDynamics' Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS and FY2027 earnings at ($0.16) EPS.

ANGO has been the subject of a number of other reports. Canaccord Genuity Group cut their price target on AngioDynamics from $13.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, October 4th. HC Wainwright restated a "buy" rating and issued a $14.00 price target on shares of AngioDynamics in a research report on Friday, October 4th.

AngioDynamics Stock Performance

Shares of ANGO stock traded down $0.36 during trading on Friday, hitting $6.73. 620,369 shares of the company were exchanged, compared to its average volume of 536,379. The firm has a market capitalization of $269.57 million, a price-to-earnings ratio of -1.46 and a beta of 0.65. The business's 50-day simple moving average is $7.16 and its 200 day simple moving average is $6.68. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $8.25.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The firm had revenue of $67.50 million during the quarter, compared to the consensus estimate of $67.93 million. During the same period in the prior year, the business earned ($0.12) EPS. The business's revenue for the quarter was down 14.2% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its position in AngioDynamics by 40.5% in the 1st quarter. BNP Paribas Financial Markets now owns 117,046 shares of the medical instruments supplier's stock valued at $687,000 after acquiring an additional 33,742 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in shares of AngioDynamics by 44.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 4,780 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of AngioDynamics by 11.9% during the first quarter. Acadian Asset Management LLC now owns 1,012,186 shares of the medical instruments supplier's stock worth $5,940,000 after buying an additional 107,764 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of AngioDynamics by 9.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 33,772 shares of the medical instruments supplier's stock worth $199,000 after buying an additional 2,821 shares in the last quarter. Finally, Bayesian Capital Management LP acquired a new stake in AngioDynamics in the 1st quarter valued at approximately $106,000. Institutional investors and hedge funds own 89.43% of the company's stock.

Insider Buying and Selling at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer bought 20,000 shares of AngioDynamics stock in a transaction on Monday, October 7th. The shares were purchased at an average cost of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the acquisition, the chief executive officer now owns 681,582 shares in the company, valued at approximately $4,109,939.46. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders bought 22,568 shares of company stock valued at $135,847. Corporate insiders own 5.10% of the company's stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.